title: Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy.
abstract: OBJECTIVE
  To assess the effects of external beam radiotherapy (EBRT) on adenoviral-mediated transgene expression in vitro and in vivo and to define an optimal strategy for combining sodium iodide symporter (NIS)-mediated (131)I therapy with EBRT.
  
  
  METHODS
  Expression of reporter genes [NIS, green fluorescent protein (GFP), beta-galactosidase (lacZ), and luciferase (Luc)] from replication-deficient adenoviruses was assessed in tumor cell lines under basal conditions and following irradiation. The effects of viral multiplicity of infection (MOI) and EBRT dose on the magnitude and duration of gene expression were determined. In vivo studies were done with Ad-CMV-GFP and Ad-RSV-Luc.
  
  
  RESULTS
  EBRT increased NIS, GFP, and beta-galactosidase expression in colorectal, head and neck, and lung cancer cells. Radiation dose and MOI were important determinants of response to EBRT, with greatest effects at higher EBRT doses and lower MOIs. Radiation exerted both transductional (through increased coxsackie-adenoviral receptor and integrin alpha(v)) and nontransductional effects, irrespective of promoter sequence (CMV, RSV, hTR, or hTERT). Analysis of the schedule of EBRT followed by viral infection revealed maximal transduction at 24 hours. Radiation maintained increasing radioiodide uptake from Ad-hTR-NIS over 6 days, in direct contrast to reducing levels in unirradiated cells. The effects of EBRT in increasing and maintaining adenovirus-mediated transgene expression were also seen in vivo using GFP- and luciferase-expressing adenoviral vectors.
  
  
  CONCLUSIONS
  Radiation increased the magnitude and duration of NIS gene expression from replication-deficient adenoviruses. The transductional effect is maximal at 24 hours, but radioiodide uptake is maintained at an elevated level over 6 days after infection.
authors.affiliation: Targeted Therapy Team, The Institute of Cancer Research, Chester Beatty Laboratories, Cancer Research UK Centre fo Cell and Molecular Biology, London, UK.
authors.forename: Mohan
authors.initials: M
authors.lastname: Hingorani
authors.forename: Christine L
authors.initials: CL
authors.lastname: White
authors.forename: Shane
authors.initials: S
authors.lastname: Zaidi
authors.forename: Andrew
authors.initials: A
authors.lastname: Merron
authors.forename: Inge
authors.initials: I
authors.lastname: Peerlinck
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gore
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Nutting
authors.forename: Hardev S
authors.initials: HS
authors.lastname: Pandha
authors.forename: Alan A
authors.initials: AA
authors.lastname: Melcher
authors.forename: Richard G
authors.initials: RG
authors.lastname: Vile
authors.forename: Georges
authors.initials: G
authors.lastname: Vassaux
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Harrington
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D005786:Gene Expression Regulation; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods; D027981:Symporters / Q000235:genetics*; D000099209:Sodium-Iodide Symporters
chemical_list: D027981:Symporters; D000099209:Sodium-Iodide Symporters